- Aptose Presents Tuspetinib (TUS) Clinical findings
- Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in R/R B cell-ALL
- BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk 1L CLL/SLL
- Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of AML
- Gilead shows New Kite Clinical Research And Real-World Evidence For Yescarta® Demonstrate Benefit From Earlier Lines Of Treatment
- IASO Bio Presented New Data of FUCASO® (Equecabtagene Autoleucel) for the Treatment of High-risk Newly Diagnosed Multiple Myeloma
- Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in CMML Patients
- IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
- J&J announces TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with R/R multiple myeloma
- Keros Therapeutics Presents Clinical Data from Elritercept (KER-050) Program
- Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333
- Novartis Scemblix® Ph III data first to show superior efficacy with a favorable safety and tolerability profile vs. SoC TKIs in adults with newly diagnosed CML
- Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with R/R CLL
- ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in R/R FLT3-mut AML Patients
- Pfizer announces ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with R/R Multiple Myeloma
- Regeneron shows Updated Linvoseltamab Data Showcasing Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
- Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
- Salarius Pharmaceuticals presents Clinical Data on Seclidemstat in Patients with MDS and CMML
- Shattuck Labs Announces Updated Positive Interim Data from the Ph 1B Dose Expansion Clinical Trial of SL-172154 + Azacitidine (AZA) in 1L HR-MDS and TP53 mutant (TP53m) AML Patients
- Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel)
- Wugen presents Phase 2 Findings of Allogeneic CAR-T, WU-CART-007, as Highly Effective and Surpassed SOC in Treating Hard-to-Treat T-ALL/LBL
